Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: GlobeNewswire
Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant’s 2018 pipeline expansionFraser Wright, Co-Founder and former Chief Technology Officer of Spark Therapeutics, to join Axovant as CTO for gene therapy programsAxovant will receive $25 million equity financing from Roivant Sciences to support clinical development of AXO-Lenti-PD and additional business developmentConference call / webcast today at 8:00am Eastern Time BASEL, Switzerland, June 06, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain. Oxford BioMedica is a world leader in lentiviral vector product development and manufacturing, and will be the
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Axon Enterprise, Inc. (NASDAQ: AXON) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $400.00 price target on the stock.MarketBeat
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safety [Yahoo! Finance]Yahoo! Finance
- Axon reimagines report writing with Draft One, a first-of-its-kind AI-powered force multiplier for public safetyPR Newswire
- Axon Enterprise (AXON) Stock Slides as Market Rises: Facts to Know Before You Trade [Yahoo! Finance]Yahoo! Finance
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 4/19/24 - Form POSASR
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEFA14A
- AXON's page on the SEC website